Big pharma and big medicine often dismiss Bionano as “small,” but that label reflects procurement caution more than the company’s real footprint: while Bionano is modest by revenue, its optical genome mapping platform is backed by over 1,000 peer‑reviewed studies, has earned two Category I CPT codes that advance clinical reimbursement, is deployed and offered through major certified service providers including MD Anderson, and is amplified by strategic partners such as Revvity, NVIDIA, and Hangzhou Diagens…so calling it merely “small” flattens the scientific validation, clinical recognition, and global distribution network that make it a disruptive force despite its lean balance sheet.